PROK
Price
$1.61
Change
-$0.15 (-8.52%)
Updated
Jul 13 closing price
Capitalization
329.35M
23 days until earnings call
Intraday BUY SELL Signals
SABS
Price
$3.73
Change
-$0.09 (-2.36%)
Updated
Jul 13 closing price
Capitalization
285.98M
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PROK vs SABS

PROK vs SABS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PROK vs. SABS commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PROK is a Buy and SABS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (PROK: $1.61 vs. SABS: $3.73)
Brand notoriety: PROK and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PROK: 107% vs. SABS: 13%
Market capitalization -- PROK: $329.35M vs. SABS: $285.98M
PROK [@Biotechnology] is valued at $329.35M. SABS’s [@Biotechnology] market capitalization is $285.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PROK’s FA Score shows that 0 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • PROK’s FA Score: 0 green, 5 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, SABS is a better buy in the long-term than PROK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PROK’s TA Score shows that 4 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).

  • PROK’s TA Score: 4 bullish, 5 bearish.
  • SABS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both PROK and SABS are a bad buy in the short-term.

Price Growth

PROK (@Biotechnology) experienced а -19.10% price change this week, while SABS (@Biotechnology) price change was -4.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

PROK is expected to report earnings on Aug 06, 2026.

SABS is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PROK($329M) has a higher market cap than SABS($286M). SABS YTD gains are higher at: -0.267 vs. PROK (-28.125). SABS has higher annual earnings (EBITDA): 2.89M vs. PROK (-149.81M). PROK has more cash in the bank: 225M vs. SABS (107M). PROK has less debt than SABS: PROK (3.78M) vs SABS (6.17M). PROK has higher revenues than SABS: PROK (889K) vs SABS (0).
PROKSABSPROK / SABS
Capitalization329M286M115%
EBITDA-149.81M2.89M-5,182%
Gain YTD-28.125-0.26710,519%
P/E RatioN/AN/A-
Revenue889K0-
Total Cash225M107M210%
Total Debt3.78M6.17M61%
TECHNICAL ANALYSIS
Technical Analysis
PROKSABS
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 26 days ago
73%
Bullish Trend 26 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PROK
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUXIX37.400.02
+0.05%
Auxier Focus Institutional
GATMX18.93N/A
N/A
Goldman Sachs International T/M Eq A
JAMEX40.89N/A
N/A
Jamestown Equity
FSTKX40.39N/A
N/A
Federated Hermes MDT Large Cap Value Svc
FVWSX28.34N/A
N/A
Fidelity Series Opportunistic Insights

PROK and

Correlation & Price change

A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
-8.52%
RXRX - PROK
50%
Loosely correlated
-7.30%
SANA - PROK
45%
Loosely correlated
-5.45%
BEAM - PROK
43%
Loosely correlated
-5.14%
CLDI - PROK
42%
Loosely correlated
-5.82%
RLYB - PROK
41%
Loosely correlated
+1.02%
More

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then REVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-2.36%
REVB - SABS
48%
Loosely correlated
-0.81%
INKT - SABS
47%
Loosely correlated
+0.90%
CYPH - SABS
46%
Loosely correlated
-0.60%
PROK - SABS
38%
Loosely correlated
-8.52%
TECX - SABS
35%
Loosely correlated
-0.09%
More